Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine

被引:70
|
作者
Zaccara, Gaetano [1 ]
Giovannelli, Fabio [1 ]
Maratea, Dario
Fadda, Valeria
Verrotti, Alberto [2 ]
机构
[1] Azienda Sanit Firenze, UO Neurol, Florence, Italy
[2] Univ G dAnnunzio, Dept Pediat, Chieti, Italy
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2013年 / 22卷 / 07期
关键词
Epilepsy; Antiepileptic drugs; Lacosamide; Eslicarbazepine; Oxcarbazepine; Adverse events; PARTIAL-ONSET SEIZURES; REFRACTORY PARTIAL EPILEPSY; ADJUNCTIVE LACOSAMIDE; CONTROLLED-TRIALS; ADULT PATIENTS; SAFETY; EFFICACY; CARBAMAZEPINE; TOXICITY; THERAPY;
D O I
10.1016/j.seizure.2013.03.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs between these three antiepileptic dugs (AEDs). Methods: We searched MEDLINE for all randomized, double-blind, placebo-controlled trials investigating therapeutic effects of fixed oral doses of ESL, LCM and OXC in patients with drug resistant epilepsy. Withdrawal rate due to AEs, percentages of patients with serious AEs, and the proportion of patients experiencing any neurological AE, nausea and vomiting were assessed for their association with the experimental drug. Analyses were performed between recommended daily doses of each AED according to the approved summary of product characteristics (SPC). Risk differences were used to evaluate the association of any AE [99% confidence intervals (CIs)] or study withdrawals because of AEs (95% CIs) with the experimental drug. Indirect comparisons between withdrawal rate and AEs dizziness, coordination abnormal/ataxia and diplopia were estimated according to network meta-analysis (Net-MA). Results: Eight randomized, placebo-controlled, double-blind trials (4 with ESL, 3 with LCM, and 1 with OXC) were included in our analysis. At high doses (OXC 1200 mg, ESL 1200 mg and LCM 400 mg) there was an increased risk of AE-related study withdrawals compared to placebo for all drugs. Several AEs were associated with the experimental drug. Both number and frequency of AEs were dose-related. At high recommended doses, patients treated with OXC withdrew from the experimental treatment significantly more frequently than patients treated with ESL and LCM. Furthermore, the AEs coordination abnormal/ataxia and diplopia were significantly more frequently observed in patients treated with OXC compared to patients treated with LCM and ESL. Conclusions: The overall tolerability of AEDs and the incidence of several neurological AEs were clearly dose-dependent. Indirect comparisons between these AEDs, taking into account dose-effect, showed that OXC may be associated with more frequent neurological AEs than LCM and ESL. (C) 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:528 / 536
页数:9
相关论文
共 3 条
  • [1] Central nervous system adverse effects of new antiepileptic drugs - A meta-analysis of placebo-controlled studies
    Zaccara, G.
    Gangemi, P. F.
    Cincotta, M.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2008, 17 (05): : 405 - 421
  • [2] Adjunctive tDCS for treatment-refractory auditory hallucinations in schizophrenia: A meta-analysis of randomized, double-blinded, sham-controlled studies
    Jiang, Wen-Long
    Cai, Dong-Bin
    Sun, Chen-Hui
    Yin, Fei
    Goerigk, Stephan
    Brunoni, Andre Russowsky
    Zhao, Xi-Wu
    Mayes, Taryn L.
    Zheng, Wei
    Xiang, Yu-Tao
    ASIAN JOURNAL OF PSYCHIATRY, 2022, 73
  • [3] Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies
    Liu, Dan
    Chen, Hao
    Song, Fang
    Ahmed, Mohamad Anis
    Wu, Hongyan
    ADVANCES IN THERAPY, 2020, 37 (10) : 4356 - 4369